A biotechnology company with deep roots in Canada says it has discovered monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis, fronto-temporal dementia, and forms of Alzheimer’s disease. Canada-born MindWalk says the discovery was made through the company’s integrated engines and research ecosystem powered by propriety […]